Home/Protocols/Melanotan I
Protocol Reference
Human trial data

Melanotan I protocol

Melanotan I / afamelanotide (alpha-MSH analog). Dosing on this page comes from a published human trial or an approved product label, cited below.

Category
Sexual & Cosmetic
Common vials
10 mg
Half-life
Extended in the implant formulation
Route in the literature
Subcutaneous implant in approved use
Evidence level
Human trial data

How Melanotan I works

A linear analog of alpha-melanocyte-stimulating hormone that acts principally at MC1 receptors, driving eumelanin production. The approved product is a slow-release implant rather than an injection.

Melanotan I dosing schedule

From the approved label. Afamelanotide is approved as Scenesse for prevention of phototoxicity in adults with erythropoietic protoporphyria — a rare light-sensitivity disorder. The route matters enormously here: the approved product is a controlled-release implant placed by a trained clinician, not the injectable powder sold as a research chemical.

PhaseAmountFrequencyNotes
Approved use16 mg implantEvery 2 months, subcutaneous implantPlaced by a healthcare professional. Not comparable to self-administered injection of reconstituted powder.

Study length: Implants placed every two months during periods of sun exposure.

Source for this schedule: Afamelanotide (Scenesse) prescribing information, erythropoietic protoporphyria indication. This reproduces what was administered in that work. It is reference information about a study, not a recommendation, and the trial population, monitoring and endpoints are part of what made it a protocol.

Reconstitution and measurement

This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for Melanotan I: 10 mg.

Open the Melanotan I calculator → Unit converter

Storage and stability

Dry powder
Cold, dark and dry. Lyophilized peptide is the stable form — keep it that way until you intend to use it.
After reconstitution
Refrigerate at 2–8 °C, protect from light, and plan around a limited window. Do not freeze a reconstituted vial — freeze-thaw damages peptides.
Mixing
Run bacteriostatic water down the inside wall of the vial rather than onto the powder, then swirl. Never shake.
Inspect before use
A clear solution is expected. Cloudiness or particles mean discard, not use.

Full storage guide → · Cloudy solution?

Reported effects

  • Label-reported effects include nausea, headache and injection-site reactions.
  • Generalised skin darkening is the expected pharmacological effect, not an adverse one.
  • Because melanocortin agonists can affect existing naevi, the label calls for skin monitoring — relevant to any melanocortin use.

Sourcing Melanotan I

Whatever you are working with, the documentation matters more than the price. Ask for a batch certificate of analysis whose lot number matches the vial you actually receive — a COA for a different batch tells you nothing about yours.

Melanotan I at Summit Research Supply → Grade a COA first

Summit is the supplier we feature and an affiliate link. Our COA checklist applies the same way to any vendor.

Sources and further reading

For laboratory research use only. This page documents what the published literature reports about Melanotan I. It is not a recommendation, not a treatment plan, and not medical advice. Compounds referenced are sold strictly as research chemicals and are not for human or veterinary use. Some supplier links are affiliate links and may earn us a commission. This never affects tier placement or review conclusions.
Summit Research Supply
Summit Research Supply — COA-verified research peptidesThird-party tested · U.S. fulfillment · new researchers save 10%
Shop →